Previous close | 15.92 |
Open | 12.00 |
Bid | 6.70 |
Ask | 14.10 |
Strike | 130.00 |
Expiry date | 2024-06-14 |
Day's range | 9.36 - 12.00 |
Contract range | N/A |
Volume | |
Open interest | 60 |
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
Moderna revealed its combination flu/COVID vaccine performed better than the two shots independently.